Biohaven Pharmaceutical Holding EBITDA Margin 2016-2022 | BHVN
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Biohaven Pharmaceutical Holding (BHVN) over the last 10 years. The current EBITDA margin for Biohaven Pharmaceutical Holding as of March 31, 2022 is .
| Biohaven Pharmaceutical Holding EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2022-03-31 |
$0.74B |
$-0.50B |
-67.48% |
| 2021-12-31 |
$0.46B |
$-0.68B |
-146.87% |
| 2021-09-30 |
$0.31B |
$-0.70B |
-226.30% |
| 2021-06-30 |
$0.19B |
$-0.72B |
-380.53% |
| 2021-03-31 |
$0.11B |
$-0.72B |
-669.16% |
| 2020-12-31 |
$0.06B |
$-0.64B |
-993.75% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$10.111B |
$0.463B |
|
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
|
